^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Gastric Adenocarcinoma

    Related cancers:
    10ms
    Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression @Aiims1742 @IamLinghua #Cancers #MedEd #MedTwitter #gastric #immune https://t.co/uAK43WcBAn (@imedverse)
    Stroma
    10ms
    From our super 🌟 @IamLinghua & colleagues @MDAndersonNews in @Cancer_Cell Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression https://t.co/KN5qJM9RpC The largest single cell RNAseq dataset in #GastricCancer https://t.co/i4H8hQLeUF (@Aiims1742)
    Stroma
    10ms
    Poster presentation! @WCGIC Latin american women with gastric adenocarcinoma and ovarian metastasis: therapeutic approaches and survival #WCGIC2023 #Oncology #OncologyResearch #GastricCancer @incanMX (@javiercboj)
    Clinical
    10ms
    Virchow’s nose! Gastric adenocarcinoma. (@CallingDrP)
    1year
    #GUTImage from the paper by Fan et al on "Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment" via https://t.co/AmjL1lk5EJ @MDAndersonNews #GastricCancer #Metastases (@Gut_BMJ)
    SOX9 (SRY-Box Transcription Factor 9)
    1year
    Great news! Our new paper: The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma is available online. Check it out here: https://t.co/NEuLKDPgsP #oncology #HER2positive #gastroesophagealcancer @_SEOM (@kimtruss)
    Clinical • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    1year
    🔥Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in #GastricAdenocarcinoma @JCOPO_ASCO https://t.co/DFgjlZNpCY 👏Excellent molecular tumorboard discussion 👉Know your🎯& know your💊! @myESMO @OncoAlert (@ArndtVogel)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    1year
    From new validation for ✅Claudin 18.2 targeting in #gastricadenocarcinoma/#GEJ to ✅IO responses in MSS #colorectalcancer, #GI23 was full of big updates. Join #TumorBoardTuesday as @MPishvaian takes us through a recap of some of the big news coming out of GI ASCO. (@JohnEbbenMDPhD)
    CLDN18 (Claudin 18)
    1year
    Good to have a potential new option for patients w met #GEJ and #gastricadenocarcinoma that improves mOS. Should new frontline testing in #GEJ include: 🔹 MSI status 🔹 HER2 🔹 PD-L1 CPS 🔹 Claudin 18.2? (@JohnEbbenMDPhD)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MSI (Microsatellite instability) • CLDN18 (Claudin 18)
    over1year
    🧐Is there a role for Trastuzumab-Deruxtecan in HER2–Low Gastric Adenocarcinoma❓ @JCO_ASCO https://t.co/92F6dcQ6fO 👉19 pts HER2 IHC 2+/ISH– -> DCR 86% mPFS 4 mOS 8 👉 21 pts HER2 IHC1+-> ORR 62% mPFS 3 mOS 8 🎯promising -> further evaluation wanted @myESMO @OncoAlert (@ArndtVogel)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    over1year
    From the @MDAndersonNews upper GI cancer research team (@AjaniSong @shumei_song @IamLinghua & colleagues) in @Gut_BMJ: Epithelial SOX9 drives progression and metastases of gastric adenocarcinoma by promoting immunosuppressive tumour microenvironment https://t.co/HCmtfAV53r (@Aiims1742)
    SOX9 (SRY-Box Transcription Factor 9)
    over1year
    Generally we treat GE Junction adenocarcinoma on line of stomach adenocarcinoma. But yes , theoretically, you are right . Pembrolizumab has sneak entry into stomach , without her2 positive, via GE junction 🙂🙂. Upper door entry . 🙂🙂 (@SuyogCancer)
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab)
    almost2years
    🎥 @NataliyaUboha of @UWCarbone talks about consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. Watch: 👉https://t.co/4e2jqSuL3Y👈 @ASCO #ASCO22 #RadOnc (@VJOncology)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    almost2years
    5 drugs recipe 🥣. FLOT Versus FLOT/Trastuzumab/Pertuzumab Perioperative Therapy of Human Epidermal Growth Factor Receptor 2–Positive Resectable Esophagogastric Adenocarcinoma: A Randomized Phase II Trial of the AIO EGA Study Group https://t.co/q0K5tvozxF (@m_khushman)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    EGFR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab)
    almost2years
    ❓How to treat ERBB2-Positive Esophagogastric Adenocarcinoma? doi:10.1001/jamaoncol.2022.2228 ✅AIO INTEGA, 88 pts, 21 sites 👉 higher efficacy for FOLFOX/trastuzumab/nivolumab compared to trastuzumab/nivolumab/ipilimumab ▶️Keynote-811 OS data awaited @OncoAlert @myESMO (@ArndtVogel)
    Clinical
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Opdivo (nivolumab) • Herceptin (trastuzumab) • Yervoy (ipilimumab) • 5-fluorouracil • leucovorin calcium
    almost2years
    Any contacts on how I can get VEGFR2 IHC please?@TristanRutland7 @DrGeeONE @JMGardnerMD @Pathologists Considering a work on gastric adenocarcinoma (@AgahuOthman)
    KDR (Kinase insert domain receptor)
    over2years
    WATCH: @DocCatenacci, of @UCCancerCenter, discusses navigating HER2 testing in gastric and gastroesophageal adenocarcinoma. #stomachcancer https://t.co/A9CUuAWOFO (@OncLive)
    HER-2 (Human epidermal growth factor receptor 2)
    over2years
    Foveolar type gastric adenoma. IHC is MUC5AC. (@KusafukaK)
    MUC5AC (Mucin 5AC)
    almost3years
    Agreed @KlempnerSam. We reflexively do: ✔️MMR ✔️HER2 ✔️PD-L1 EBV we are only doing it in gastric adenocarcinoma. In our cohort, ~4% Gastric. None esophageal. #STCSM #Immunotherapy (@pashtoonkasi)
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    3years
    Agree. We need to explain it clearly to our patients if their PDL1 is less than 5 (referring to pts with metastatic gastric adenocarcinomas). (@doctorC369)
    Clinical
    |
    PD-L1 (Programmed death ligand 1)
    3years
    42yo F, gastric adenocarcinoma, uT3N+M0, dMMR (MLH1/PMS2), HER2 0, PD-L1 CPS 10, NTRK neg. ECOG 0. Your choice: @DocCatenacci @YJanjigianMD @ILSONDavid @clearyonc @GIcancerDoc @agrothey @pashtoonkasi @MPishvaian @CathyEngMD @jordanberlin5 @KristenCiombor @drlauragoff (@AJacomeMD)
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • MLH1 (MutL homolog 1) • PMS2 (PMS1 protein homolog 2) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    MSI-H/dMMR
    over3years
    ✨On the great news side✨ @OncoAlert FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas. Know of some precious patients who would have loved this. @gary_lyman (@NicoleKuderer)
    Clinical • FDA event
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    over3years
    FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas https://t.co/gTbK0BqKc2 (@sheik2411)
    FDA event
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    over3years
    🚨⭐️FDA approves fam-trastuzumab deruxtecan-nxki for HER2-positive gastric adenocarcinomas @FDAOncology https://t.co/kjxWICwXDg (@VivekSubbiah)
    FDA event
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)